Thus, SOCS3 may be used as a novel biomarker predicting the response to targeted drugs and it was of great value to further elucidate the role and mechanism underlying SOCS3 expression in CML cells. This evidence concerns the gene SOCS3 and chronic myelogenous leukemia, BCR-ABL1 positive.